{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=74",
    "query": {
      "condition": "Safety Study",
      "page": 74
    },
    "page_size": 10
  },
  "pagination": {
    "page": 74,
    "page_size": 10,
    "total_count": 33600,
    "total_pages": 3360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=75&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=73&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T18:01:33.421Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01786915",
      "title": "Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Bendavia 10mg",
          "type": "DRUG"
        },
        {
          "name": "Bendavia 50mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mighty Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2013-02",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2014-04-02",
      "last_synced_at": "2026-11-20T18:01:33.421Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01786915"
    },
    {
      "nct_id": "NCT02740335",
      "title": "Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Significant Bleeding Risk"
      ],
      "interventions": [
        {
          "name": "Octaplex",
          "type": "DRUG"
        },
        {
          "name": "Beriplex P/N (Kcentra)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2017-06-08",
      "completion_date": "2022-02-23",
      "has_results": true,
      "last_update_posted_date": "2023-03-08",
      "last_synced_at": "2026-11-20T18:01:33.421Z",
      "location_count": 22,
      "location_summary": "Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02740335"
    },
    {
      "nct_id": "NCT01543763",
      "title": "Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "PZP115891, PCI-24781",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pamela Munster",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2012-06-25",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-03-21",
      "last_synced_at": "2026-11-20T18:01:33.421Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01543763"
    },
    {
      "nct_id": "NCT03948763",
      "title": "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Pancreatic Neoplasms",
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "V941",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2019-06-26",
      "completion_date": "2022-08-25",
      "has_results": true,
      "last_update_posted_date": "2025-01-28",
      "last_synced_at": "2026-11-20T18:01:33.421Z",
      "location_count": 10,
      "location_summary": "Gilbert, Arizona • Duarte, California • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03948763"
    },
    {
      "nct_id": "NCT04136821",
      "title": "The Long-term Effects of Oceanix™ on Resistance Training Adaptations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Oxidative Stress",
        "Muscle Strength",
        "Resistance Training",
        "Body Composition",
        "Muscle Damage"
      ],
      "interventions": [
        {
          "name": "Oceanix",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Resistance Training",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Applied Science & Performance Institute",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 25,
      "start_date": "2019-09-30",
      "completion_date": "2020-01-31",
      "has_results": false,
      "last_update_posted_date": "2020-02-27",
      "last_synced_at": "2026-11-20T18:01:33.421Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04136821"
    },
    {
      "nct_id": "NCT05604521",
      "title": "A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria",
        "Malaria,Falciparum"
      ],
      "interventions": [
        {
          "name": "PfSPZ Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PfSPZ Challenge (7G8)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanaria Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 31,
      "start_date": "2022-12-06",
      "completion_date": "2023-09-05",
      "has_results": true,
      "last_update_posted_date": "2024-11-25",
      "last_synced_at": "2026-11-20T18:01:33.421Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05604521"
    },
    {
      "nct_id": "NCT06326814",
      "title": "A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria"
      ],
      "interventions": [
        {
          "name": "Humanized anti-Factor Bb monoclonal antibody",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 54,
      "start_date": "2021-10-11",
      "completion_date": "2023-05-05",
      "has_results": false,
      "last_update_posted_date": "2024-03-22",
      "last_synced_at": "2026-11-20T18:01:33.421Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06326814"
    },
    {
      "nct_id": "NCT07137416",
      "title": "Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Invasive Breast Carcinoma",
        "Locally Advanced Breast Carcinoma",
        "Metastatic Breast Carcinoma",
        "Metastatic HER2-Low Breast Carcinoma",
        "Metastatic HER2-Positive Breast Carcinoma",
        "Metastatic Hormone Receptor-Positive Breast Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Unresectable Breast Carcinoma",
        "Unresectable HER2-Low Breast Carcinoma",
        "Unresectable HER2-Positive Breast Carcinoma",
        "Unresectable Hormone Receptor-Positive Breast Carcinoma",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Pidnarulex",
          "type": "DRUG"
        },
        {
          "name": "Radiologic Imaging Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2026-10-06",
      "completion_date": "2028-01-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-20T18:01:33.421Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • St Louis, Missouri",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07137416"
    },
    {
      "nct_id": "NCT01314716",
      "title": "Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bronchiectasis"
      ],
      "interventions": [
        {
          "name": "AZLI",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 274,
      "start_date": "2011-04",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2014-04-16",
      "last_synced_at": "2026-11-20T18:01:33.421Z",
      "location_count": 33,
      "location_summary": "Florence, Alabama • Flagstaff, Arizona • Peoria, Arizona + 30 more",
      "locations": [
        {
          "city": "Florence",
          "state": "Alabama"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01314716"
    },
    {
      "nct_id": "NCT00825916",
      "title": "A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Scar Prevention",
        "Scar Reduction"
      ],
      "interventions": [
        {
          "name": "AZX100 Drug Product",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Capstone Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 59,
      "start_date": "2009-03",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2012-10-11",
      "last_synced_at": "2026-11-20T18:01:33.421Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Austin, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00825916"
    }
  ]
}